Ir directamente a la información del producto
1 de 3

Biolab Shop

Inferno Fat Blaze 5300 mcg, 30 caps

Inferno Fat Blaze 5300 mcg, 30 caps

Precio habitual £95.00 GBP
Precio habitual Precio de oferta £95.00 GBP
Oferta Agotado
Impuestos incluidos. Los gastos de envío se calculan en la pantalla de pago.

INFERNO FAT BLAZE

It is a combination of 3 ingredients: SLU- PP-332 is the most advanced formula for weight reduction - it forces the use of fatty acids as an energy source and puts the body into a state that is induced by exercise or fasting. Accelerates metabolic rate and weight reduction without changes in physical activity or diet. It has a protective effect on the heart and liver. In combination with Cardarine, it improves insulin sensitivity of tissues and increases body performance. SLU-PP-332 potentiates the effect of Lipotropin, which additionally releases fatty acids from cells - so the effectiveness of Lipotropin increases significantly without the need to increase the dose. 

SLU-PP-332 - is a synthetic compound that has attracted considerable attention for its potential benefits, particularly in the areas of metabolic health and weight control. Here are the key benefits associated with SLU-PP-332 : 

1. Weight loss: SLU-PP-332 has shown the ability to promote weight loss in experimental studies, mainly in mice. It has been shown to help mice lose a significant percentage of body weight without affecting appetite or food intake

https://www.eurekalert.org/news-releases/1002687

2. Fat reduction: SLU-PP-332 administration is associated with a significant reduction in body fat mass without a corresponding decrease in overall body weight. This suggests that it may specifically target fat accumulation

https://www.labroots.com/trending/cardiology/26023/unlocking-potential-exercise-pill-err-agonist-slu-pp-332

3. Preservation of muscle mass: One notable advantage of SLU-PP-332 is its potential to maintain muscle mass during weight loss, which is often a challenge in traditional weight loss efforts

https://bnn.network/breaking-news/health/new-exercise-mimicking-drug-a-potential-game-changer-in-treating-obesity-diabetes-and-muscle-loss/

4. Exercise mimicry: SLU-PP-332 has been described as an exercise-mimicking drug. It appears to replicate some of the metabolic benefits typically associated with exercise, making it a potential option for people who cannot engage in physical activity or as an adjunct to exercise routines

https://www.technologynetworks.com/drug-discovery/news/exercise-mimicking-drug-helps-mice-lose-weight-and-boost-endurance-379473

5. Metabolic syndrome mitigation: Studies suggest that SLU-PP-332 may alleviate metabolic syndrome, a group of conditions that increase the risk of heart disease, stroke and type 2 diabetes

https://jpet.aspetjournals.org/content/early/2023/09/22/jpet.123.001733

Cardarine, initially developed as a potential drug for metabolic and cardiovascular disorders, belongs to a class of chemicals known as PPAR (peroxisome proliferator-activated receptor) delta agonists. It works by activating PPAR delta receptors in the body, which play a key role in regulating various metabolic processes, including fat burning and energy utilization.

Its benefits include:

1. Increased fat loss

2. Improved endurance and performance

3. Preservation of lean muscle mass

4. Improved cardiovascular health

5. Potential anti-inflammatory effects

 

AOD9604 - Lipotropin is a peptide fragment of the C-terminus or lipolytic domain of hGH (hGH 177-191), with an additional tyrosine residue at the N-terminus for stabilization. In vitro and in vivo experiments showed similar effects of AOD9604 and hGH on lipid metabolism when chronically applied in mice. Interestingly, AOD9604 mimics the effects of hGH on lipid metabolism, without growth-promoting or pro-diabetic effects. Six human clinical trials of AOD9604 hexadecapeptide were conducted between 2001 and 2006, involving 893 clinically obese healthy adults in all but one study, and form the basis of this safety assessment. Details of each study are listed in the supplemental data. The first 3 studies were dose escalation studies examining the acute effects of different doses and two routes of administration (i.v. and oral) in healthy or obese men. These single-dose studies were followed by a 7-day multiple-dose study (METAOD004), and two long-term clinical trials (METAOD005 and METAOD006) investigating the safety and tolerability of chronic oral treatment with AOD9604.

Ver todos los detalles

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)